Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioVaxys Technology Corp. BVAXF


Primary Symbol: C.BIOV

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.


CSE:BIOV - Post by User

BioVaxys Technology Corp.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(328)
•••
Post by moneywagonon Jun 15, 2022 2:14pm
107 Views
Post# 34758854

BIOV COME BACK HERE NOW~DATS ME ON BID@.10 FINISH MY FILL!!

BIOV COME BACK HERE NOW~DATS ME ON BID@.10 FINISH MY FILL!! PROGRESS...and more progress......that is all I am looking for in this ridiculous market. Any other time our sp would soar on this news. Great Job I see the FDA holding a trophy for us in the near off distance!! hahaha

All the shareprices will float to MERIT value when the panic ones have learnt a new learning curve in investing 101.....PAY tience.

If you are buying when FOMO hits a stock...........you are buying too high PERIOD!!
Ya gotta sneak in when everybody is running da other way!! 

Shout lout Longs HEY FRANKY SLAP me a couple @.10's I know you're treasure chest is loaded hahahha 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities